Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Reduced by Pacer Advisors Inc.

Pacer Advisors Inc. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 20,055 shares of the biotechnology company’s stock after selling 932 shares during the quarter. Pacer Advisors Inc.’s holdings in Sarepta Therapeutics were worth $2,438,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. grew its position in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank increased its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. UMB Bank n.a. raised its holdings in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 197 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $59,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $113.72 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The company has a market cap of $10.86 billion, a PE ratio of 90.98 and a beta of 0.77. The stock’s 50-day moving average price is $122.80 and its two-hundred day moving average price is $127.23.

Analyst Upgrades and Downgrades

Several analysts recently commented on SRPT shares. Robert W. Baird lowered their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Evercore ISI lowered their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday, January 27th. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Insider Activity

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.